Video

ESC 2017: Risk for Heart Failure Modulates the Effectiveness of Empagliflozin?

Published: 15 Sep 2017

  • Views:

    Views Icon 356

  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

This interview with Javed Butler from Stony Brook University, New York, USA discusses Does the Risk for Heart Failure Modulates the Effectiveness of Empagliflozin on Heart Failure Hospitalization or Cardiovascular Death in Patients with Type 2 Diabetes without Heart Failure? 

Filmed by Radcliffe Cardiology on-site at ESC 2017.